Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase . Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Global non-alcoholic Steatohepatitis market is expected to garner $1693.2 million by 2020 growing at a CAGR of 25.6% during 2014-2020.
Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. The market growth is restricted by factors such as NASH’s complex and enigmatic physiological structure and inefficient diagnostics technology; these factors could also prolong the commercialization process for NASH therapeutics. Nevertheless, certain key players competing in the market are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. The results of a recent clinical trial conducted by Genfit satisfied concerns of the EMA (European Medicines Agency), regarding the efficacy and safety of GFT5o5 as therapeutics for NASH. The EMA finally recommended that the development of GFT5o5 as a therapeutic drug progress to Phase III of the clinical trial. Additionally, Dainippon Sumitomo Pharma (DSP), a partner of Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the safety and efficacy of one daily dose of OCA in 200 adult NASH patients. The trial is expected to be completed in the first half of 2016.
Geographically, the NASH therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Geographical analysis of NASH therapeutics is conducted with reference to research and commercialization. North America, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. It is also one of the regions with the most cases of NASH and other non-alcoholic fatty liver diseases. European countries are equally contributing to the growth of the NASH therapeutics market in terms of research and commercialization; however, failure to comply with regulations and decreased number of research initiatives causes them to be relegated to the second place in this market. With regard to developing economies, Asia-Pacific region is one of the fastest growing markets for NASH therapeutics and is expected to have a double digit growth rate during the analysis period. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people afflicted with these conditions- a number which is expected to increase up to 30 fold by 2030. Furthermore, the exorbitant price of the physical therapeutics currently used to treat fatty liver diseases is raising the demand for pharmaceutical therapies as they are comparatively economical.
Global Non-alcoholic Steatohepatitis market is categorized into pipeline therapeutic types and geography.
MARKET BY THERAPEUTICS
MARKET BY GEOGRAPHY
The Global Chlorhexidine Gluconate (CHG) Solution market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Chlorhexidine Gluconate (CHG) Solution market, especially in North America, Europe, ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Chlorhexidine Gluconate (CHG) Solution market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Chlorhexidine Gluconate (CHG) Solution in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, ...
November 2017 | $4660 |View Details>>
In 2016, the Chlorhexidine Gluconate (CHG) Solution market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Xttrium Medichem ...
November 2017 | $3360 |View Details>>
In 2016, the Europe Chlorhexidine Gluconate (CHG) Solution market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Chlorhexidine Gluconate (CHG) Solution in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey ...
November 2017 | $4660 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research